Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 / F. Pietrantonio, M.C. Garassino, V. Torri, F. De Braud. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:10(2012), pp. mds332.2771-mds332.2772. [10.1093/annonc/mds332]

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

F. Pietrantonio;F. De Braud
2012

fluorouracil; leucovorin; survival
Settore MED/06 - Oncologia Medica
2012
Article (author)
File in questo prodotto:
File Dimensione Formato  
mds332.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 147.12 kB
Formato Adobe PDF
147.12 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/563683
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact